Daewoong Pharmaceutical, Tion Lab Enter Phase 1 Trial in Korea for 'Once-Monthly Obesity Treatment'
IND Approved for Semaglutide-Based Long-Acting Injectable "TION-L002"
Daewoong Pharmaceutical said on November 19 that the Ministry of Food and Drug Safety had approved the investigational new drug (IND) application for a Phase 1 clinical trial of TION-L002, a once-monthly, long-acting candidate for obesity treatment that it is co-developing with Tion Lab Therapeutics.
A once-monthly, long-acting semaglutide injection being co-developed by Daewoong Pharmaceutical and TionLab Therapeutics. Daewoong Pharmaceutical
View original imageTION-L002 is a long-acting injectable being developed based on semaglutide, an active ingredient used to treat obesity and diabetes. The goal is to extend the dosing interval for existing once-weekly semaglutide products to once a month. If development is successful, the number of injections per year could be reduced from 52 to 12.
In the Phase 1 trial, the two companies plan to evaluate TION-L002's safety and pharmacokinetic characteristics and compare it with a control drug to assess the potential of developing a long-acting formulation. Based on the trial results, they also plan to seek global partners and pursue entry into overseas markets.
TION-L002 uses Daewoong Pharmaceutical's CURE® drug-delivery platform and Tion Lab Therapeutics' Quject®Sphere. By combining the two companies' platforms, the formulation is designed to prevent the drug from being released all at once immediately after injection and instead release it at a steady rate over an extended period.
Daewoong Pharmaceutical's CURE is a technology that produces uniform drug particle sizes through an inlet-nozzle process. Tion Lab Therapeutics' Quject®Sphere is a technology that coats drug particles with a specialized composition to suppress the initial release of the drug.
Deoksu Im, CEO of Tion Lab Therapeutics, said, "TION-L002, which we have been developing in collaboration with Daewoong Pharmaceutical, has entered the clinical stage in earnest. Building on the formulation technologies of both companies, we will develop a long-acting obesity treatment that is expected to deliver effects comparable to existing treatments with just one dose a month."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seongsu Park, CEO of Daewoong Pharmaceutical, said, "Approval of the IND for this long-acting injectable will further strengthen our obesity-treatment portfolio. Based on data from clinical trials in Korea, we will expand our global partnerships and accelerate development to provide patients around the world with more convenient treatment options."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.